Bayer daagt Johnson & Johnson voor de rechter om misleidende reclame voor prostaatkankermedicijn Key takeaways Bayer heeft een rechtszaak aangespannen tegen Johnson & Johnson, omdat het bedrijf beweert dat hun marketingcampagne voor het prostaatkankermedicijn Erleada misleidend en schadelijk is. Bayer beweert dat Johnson & Johnson ten onrechte stelt dat Erleada het risico op overlijden aan prostaatkanker met 51 procent vermindert in vergelijking met het medicijn Nubeqa van Bayer. […]

Bayer daagt Johnson & Johnson voor de rechter om misleidende reclame voor prostaatkankermedicijn #Bayer #JohnsonJohnson #Prostaatkanker #Erleada #Nubeqa

🔷 Approval is supported by positive Phase III ARANOTE data, enabling physicians to better tailor treatment plans for men with mHSPC.

🔗 Read more: bit.ly/ONCOnews04Fe...

#ONCOnews #OncoAlert #OncEd #Nubeqa #Darolutamide #ProstateCancer #mHSPC #ClinicalTrials

"Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market

#menshealth #NICE #prostatecancer #hormonesensitiveprostatecancer #HSPC #abiraterone #JnJ #Zytiga #brandedpharmaceuticals #NICEguidance #advancedHSPC #androgendeprivationtherapy #ADT #Bayer #Nubeqa #Astellas #Xtandi #Erleada #genericmedicines #ProstateCancerUK
zurl.co/fzdbT

Bayer's prostate cancer drug Nubeqa cleared for NHS use Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

#menshealth #NICErecommended #Bayer #prostatecancer #Nubeqa #darolutamide #Nubeqaregimen #hormonesensitiveprostatecancer #HSPC #androgendeprivationtherapy #ProstateCancerUK #advancedHSPC #ARANOTEtrial #castrationresistantprostatecancer #CRPC #mHSPC #NationalProstateCancerAudit #NPCA
zurl.co/dDIIm

Bayer scores UK NICE nod for Nubeqa in prostate cancer NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.

News for prostate cancer patients in England and Wales — NICE has recommended Bayer’s Nubeqa plus ADT as a new NHS treatment option for men with hormone-sensitive metastatic prostate cancer.

#News #ProstateCancer #NICE #Bayer #Nubeqa #Darolutamide #CancerResearch #MensHealth #Oncology #NHS

Bayer scores UK NICE nod for Nubeqa in prostate cancer NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.

News for prostate cancer patients in England and Wales — NICE has recommended Bayer’s Nubeqa plus ADT as a new NHS treatment option for men with hormone-sensitive metastatic prostate cancer.

#News #ProstateCancer #NICE #Bayer #Nubeqa #Darolutamide #CancerResearch #MensHealth #Oncology #NHS

Darolutamide (Nubeqa) 2025 Updates: A Patient Guide to Treatment for Prostate Cancer - OncoDaily Learn more about Darolutamide (Nubeqa), its uses in cancer, dosage, side effects, expectation.

Darolutamide (Nubeqa) 2025 Updates: A Patient Guide to Treatment for Prostate Cancer

oncodaily.com/drugs/darolu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Darolutamide #Nubeqa #ProstateCancer

Darolutamide (Nubeqa) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily darolutamide (nubeqa) is approved to treat of nmCRPC and mHSPC. Learn about its uses, side effects, dosage and expectations.

Darolutamide (Nubeqa) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/darolu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Darolutamide #Nubeqa #ProstateCancer #CSPC